{"id":"icp-332-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Hematologic abnormalities"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3654090","moleculeType":"Small molecule","molecularWeight":"871.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ICP-332 inhibits tyrosine kinase signaling involved in tumor cell proliferation and survival. The drug is designed to selectively target aberrant kinase activity in cancer, potentially blocking multiple pathways that drive malignant cell growth. It is being developed as an oral small-molecule therapeutic for hematologic and solid malignancies.","oneSentence":"ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:25.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07378527","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria","status":"NOT_YET_RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2026-03","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":344},{"nctId":"NCT07236099","phase":"PHASE2","title":"Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2025-11-27","conditions":"Prurigo Nodularis (PN)","enrollment":135},{"nctId":"NCT07251998","phase":"PHASE2","title":"Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2025-12-22","conditions":"Plaque Psoriasis","enrollment":172},{"nctId":"NCT06775860","phase":"PHASE3","title":"ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2024-11-14","conditions":"Atopic Dermatitis","enrollment":552},{"nctId":"NCT07047612","phase":"PHASE2, PHASE3","title":"ICP-332 in Subjects With Non-segmental Vitiligo","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2025-05-09","conditions":"Non Segmental Vitiligo","enrollment":603},{"nctId":"NCT06530966","phase":"PHASE1","title":"Phase I Study of ICP-332 in Healthy Subjects","status":"RECRUITING","sponsor":"InnoCare Pharma Inc.","startDate":"2024-07-23","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT05702268","phase":"PHASE2","title":"Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2023-03-18","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":75},{"nctId":"NCT05399030","phase":"PHASE1","title":"A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects","status":"COMPLETED","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2021-08-14","conditions":"Healthy Subjects","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ICP-332 Tablets","genericName":"ICP-332 Tablets","companyName":"Beijing InnoCare Pharma Tech Co., Ltd.","companyId":"beijing-innocare-pharma-tech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells. Used for Hematologic malignancies (phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}